New Preclinical Data for EDP-235, Enanta’s Oral Protease Inhibitor Specifically Designed for the Treatment of COVID-19, to be Presented at ISRIV-WHO Virtual 2021 Conference: COVID-19, Influenza and RSV: Surveillance-Informed Prevention and Treatment
October 06 2021 - 8:16AM
Business Wire
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage
biotechnology company dedicated to creating small molecule drugs
for viral infections and liver diseases, today announced that new
preclinical data for EDP-235, its lead oral protease inhibitor
specifically designed for the treatment of COVID-19, will be
presented at the International Society for Influenza and Other
Respiratory Virus Diseases (ISIRV)-World Health Organization
Virtual Conference (WHO): COVID-19, Influenza and RSV:
Surveillance-Informed Prevention and Treatment. The conference is
being held virtually on October 19 – October 21, 2021.
Poster Presentation: Date:
October 19, 2021 Time: 8:00 a.m. CET Poster #120:
“EDP-235, A Potential Oral, Once-Daily Antiviral Treatment and
Preventative for COVID-19” Presenter: Li-Juan Jiang,
Ph.D.
Posters will be available to view on the conference platform
during the conference and for three months thereafter. Further
information about the ISIRV-WHO Virtual Conference 2021 can be
found here.
About Enanta Enanta is using its robust, chemistry-driven
approach and drug discovery capabilities to become a leader in the
discovery and development of small molecule drugs for the treatment
of viral infections and liver diseases. Enanta’s research and
development efforts have produced clinical candidates currently in
development for the following disease targets: respiratory
syncytial virus (RSV), hepatitis B virus (HBV) and SARS-CoV-2
(COVID-19). Enanta is also conducting research in human
metapneumovirus (hMPV).
Enanta’s research and development activities are funded by
royalties from hepatitis C virus (HCV) products developed under its
collaboration with AbbVie. Glecaprevir, a protease inhibitor
discovered by Enanta, is sold by AbbVie in numerous countries as
part of its leading treatment for chronic HCV infection under the
tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.)
(glecaprevir/pibrentasvir). Please visit www.enanta.com for more
information.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211006005607/en/
Media and Investor Contact Jennifer Viera 617-744-3848
jviera@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Apr 2023 to Apr 2024